Loading...
Use of ex vivo patient derived tumor organotypic spheroids to identify combination therapies for HER2 mutant non small cell lung cancer
PURPOSE: Evaluating drug responses using primary patient derived cells ex vivo represents a potentially rapid and efficient approach to screening for new treatment approaches. Here, we sought to identify neratinib combinations in HER2 mutant non-small cell lung cancer (NSCLC) patient xenograft deriv...
Na minha lista:
| Udgivet i: | Clin Cancer Res |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
2020
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7967092/ https://ncbi.nlm.nih.gov/pubmed/32034078 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-19-1844 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|